CAS: 16856-18-1; (S)-2-Amino-5-Guanidinopentanoic Acid 2-Oxopentanedioic Acid Salt

相似化合物

4320-30-3 7675-83-4 5256-76-8

上下游产品

L-arginine dimethyl 2,2-dichloro-1,5-pentanedioate

L-精氨酸,Dimethyl 2,2-Dichloro-1,5-Pentanedioate 以 水 用作溶剂,化学反应生成L-精氨酸-Alpha-酮戊二酸盐
参考文献:Process For Preparation Of Alpha-Ketoglutaric Acid
标题:Process For Preparation Of Alpha-Ketoglutaric Acid
摘要:一种制备α-酮戊二酸的方法,适用于制备l-精氨酸α-酮戊二酸1:1和2:1,包括以下步骤:(A)将二氯乙酸甲酯和丙烯酸甲酯与甲氧基钠反应,得到二甲基2,2-二氯戊二酸酯;(B)将步骤(A)中得到的二甲基2,2-二氯戊二酸酯与氢氧化物溶液反应,得到粗α-酮戊二酸水溶液;(C)纯化粗α-酮戊二酸水溶液,得到纯化的α-酮戊二酸水溶液;(D)通过加水调节纯化的α-酮戊二酸水溶液的浓度,从而获得纯化的α-酮戊二酸水溶液的收率约为75%.本发明的方法避免了使用大量的有机溶剂,具有显著的高收率,能够实现低成本的大规模生产并缩短生产时间.

专利信息

专利号:US-2008096242-A1
优先权日:2004-09-01
标 题 :Enhanced Substrate Conversion Efficiency Of Fermentation Processes
发明人：SANDERS JOHAN P M; WEUSTHUIS RUUD A; MOOIBROEK ANDREAS
权利人:AGROTECHNOLOGY AND FOOD INNOVA
摘要:The present invention relates to the field of fermentation technology. In particular the invention relates to fermentation processes for the production of a first and a second fermentation product by a single production organism wherein the first product is in a more reduced state than the substrate and the second fermentation product is in a more oxidised state than the substrate yet in a less oxidised state than the final oxidation product CO 2 , such that the concurrent synthesis of the first and second product in the organism allows recycling of reducing power and can be performed under (partially) anaerobic conditions. The invention also relates to such processes in which the first and second fermentation products are capable of forming a(n) (insoluble) complex or salt.

专利号:US-2005090545-A1
优先权日:2003-10-22
标题:Nitric oxide topical technology
发明人：LEITMAN LORN; BARNI GUSTAVO
摘要:This invention with a new compound enables application of L-Arginine made with arginine alpha-ketoglutarate, arginine pyroglutamate, arginine ketoisocaproate and ornithine alpha-ketoglutarate to work together and separately along with other ingredients, topically. It is intended to improve the process by which these compounds work in the human organism. The invention is based on the facts that L-Arginine is: known to be the immediate precursor of the endogenous vasodilator substance found in the arterial blood vessels called “Endothelium-Derived Relaxing Factorâ€? (EDRF) required for protein synthesis and, depending on the organism's needs, can either be metabolized to support glucose synthesis or catabolized to produce energy This simplified “noninvasiveâ€? application surpasses gastrointestinal digestion so the compounds will not degrade and favoring absorption into the circulatory system thus enhancing the compounds' effects and at much lower dosage levels than oral or parenteral administration. A composition comprising L-Arginine to be used topically that creates increases in muscle size, strength, endurance andpower output.